Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Rini, Brian I.; Atkins, Michael B.; Plimack, Elizabeth R.; Soulieres, Denis; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Alekseev, Boris; Melichar, Bohuslav; Shparyk, Yaroslav; Kondoh, Chihiro; Langiewicz, Przemyslaw; Wood, Lori A.; Hammers, Hans; Silber, Cynthia G.; Haber, Barbara; Jensen, Erin; Chen, Mei; Powles, Thomas

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Autor(en):

Rini, Brian I.; Atkins, Michael B.; Plimack, Elizabeth R.; Soulieres, Denis; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Alekseev, Boris; Melichar, Bohuslav; Shparyk, Yaroslav; Kondoh, Chihiro; Langiewicz, Przemyslaw; Wood, Lori A.; Hammers, Hans; Silber, Cynthia G.; Haber, Barbara; Jensen, Erin; Chen, Mei; Powles, Thomas

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

European Urology Oncology (2022), Bd. 5, H. 2, S. 225-234

Verlagsangabe:

Amsterdam : Elsevier

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.euo.2021.05.007

ISSN:

2588-9311